Phosphatidylserine: Paving the Way for a New Era in Cancer Therapies

Abstract

Cancer has long been a leading cause of death globally. These days, many clinically approved Immunoactive Agents can be used alone or in combination with other anticancer medications. This lipid plays a vital role in the growth and proliferation of cancer cells and has been identified as a potential target for cancer treatment. Recent research has focused on using phosphatidylserine-targeting agents in the treatment of several class of cancer, like breast, lung, and prostate. One of the most promising approaches involves using phosphatidylserine-targeting antibodies, which have been shown to target cancer cells while leaving healthy cells unharmed selectively. These antibodies specifically target to phosphatidylserine molecules located on the exterior membrane of cancer cells, triggering a series of events that ultimately destroy the cancer cells. By incorporating phosphatidylserine into the liposome membrane, researchers have designed liposomes to specifically target cancer cells, thereby enabling more efficient drug delivery. and improved cancer treatment outcomes. Phosphatidylserine has active ingredients that are currently undergoing clinical trials for potential use in treating various types of cancer. On the role of phosphatidylserine in cancer and biophysical biology, the review summarizes latest research, as well as related prospective clinical and preclinical trials such as immunotherapy and biomarkers. A new indication of future PS implementations in cancer therapy appears to be provided as well.